Farma

Oppgang Kommer
11.04.2019 kl 10:36 1173

Beware of AUA 2019 den 03 - 06.05 folks, der har Photocure tilsammen fått avsatt 3t og 15 min til demonstrasjoner fordelt på en 2 timer sesjon og en på 1 og 15 min.
Dette må være ny rekord for avsatt tid til et selskap, og et lite selskap sådan, så langt, for PHO er ikke et lite selskap ved AUA i 2020.

Det forventes store ting fra Photocure der, og det er sendt børsmelding om dette på forhånd..
____________________________________________________________________________________________________________________
08/04-2019 11:15:12: (PHO) Photocure: New Data on Cysview® to be presented at the upcoming AUA 2019 Annual Meeting
Oslo, Norway, April 8, 2019: Photocure ASA (PHO:OSE) announced today that
Photocure will be exhibiting Blue Light Cystoscopy (BLCT) with Cysview in Booth
2214, during the American Urological Association Meeting (AUA 2019) in Chicago
May 3rd-6th.
On the booth urologists will have the opportunity to experience BLC with
Cysview, using both the rigid and flexible equipment.

BLC with Cysview will also be presented during plenary and poster sessions at
the AUA annual meeting including:

May 3, 2019 (FRIDAY)

· 10:25 AM to 11:40 AM: Blue Light Cystoscopy for the diagnosis of Bladder
Cancer by Dr. Badrinth Konety from University of Minnesota (Minneapolis, MN),
MCP S105
· 4:45PM - 5:45 PM: Surgical Techniques: Tips & Tricks: Oncology Dr. Lotan,
UTSW, (Dallas Tx) will present BLC with Cysview Flexible during the session
W375e

May 4, 2019 (SATURDAY)

· 3:30 PM - 5:30 PM: Poster presentation: Flexible Blue Light Cystoscopy with
Hexaminolevulinate provides opportunity to finalize Diagnosis and Treatment of
Non-Muscle Invasive Bladder Cancer in the Outpatient Clinic. Results from a
Nordic Registry Study, W181ab

About Bladder Cancer
Bladder cancer is the sixth most commonly diagnosed cancer in the US and is the
fourth most common cancer found in men in the US.(1, 2) It is estimated that
there will be 80,470 new cases of bladder cancer and 17,670 deaths due to
bladder cancer in 2019.(3) Risk factors for bladder cancer include advancing
age, cigarette smoking, occupational exposure to dyes, tar, rubber and solvent,
and chronic bladder irritation and infections.(4) Bladder cancer is one of the
most expensive cancers to manage. It is estimated that upwards of $5.71 billion
will be spent on bladder cancer in the US in the year 2020.(5)

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall.(4) NMIBC is in the inner layer of cells.(3) These
cancers are the most common (75%) of all bladder cancer cases and include the
subtypes carcinoma in situ (CIS), Ta and T1 lesions.(5) MIBC is when the cancer
has grown into deeper layers of the bladder wall.(2) These cancers, including
subtypes T2, T3 and T4, are more likely to spread and are harder to treat.(6)

About Hexvix®/Cysview® (hexaminolevulinate HCl)
Hexvix®/Cysview® is a drug that is selectively taken up by tumor cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLCT
with Hexvix® /Cysview® improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.

Cysview® is the tradename in the US and Canada, Hexvix® is the tradename in all
other markets. Photocure is commercializing Cysview® /Hexvix® directly in the US
and the Nordic region and has strategic partnerships for the commercialization
of Hexvix®/Cysview® in Europe, Canada, Australia and New Zealand. Please refer
to https://bit.ly/2wzqSQQ for further information on our commercial partners.

Ekstern link: https://newsweb.oslobors.no/message/473933



Redigert 11.04.2019 kl 10:38

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.